ClinicalTrials.gg
CompletedNCT06821464Updated Jul 2, 2026

A Trial of HRS-9813 in Healthy Subjects

A Phase 1 interventional study of HRS-9813 and HRS-9813 in Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Enrollment
40th of 60
45 · median 83
Started
2025
with 9 others
Phase 1
20 of 67
5 open now
Registered
46th of 67
by date
Lead sponsor
3 of 67
Guangdong Hengrui Pharmaceutical Co., Ltd

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 40th largest by enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2025, is one of 20 in phase 1, and was the 46th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form before the start of activities related to this trial, and be able to fully understand the procedures, methods, contents and possible adverse reactions of this trial, and be willing to strictly abide by the clinical trial protocol to complete this trial.
  2. Aged 18-45 years (inclusive), healthy male or female;
  3. Male weight ≥ 50 kg, female weight ≥ 45 kg, and (BMI): 19-26 kg/m2 (inclusive), body mass index (BMI) = weight (kg)/(height/100)2 (m2);
  4. Physical examination, vital signs, 12-lead , chest anteroposterior and lateral radiographs, abdominal ultrasound and laboratory tests during the screening and baseline periods were normal, or slightly abnormal but clinically insignificant as determined by the researchers;
  5. Female subjects with fertility and male subjects whose partners are women of childbearing age have taken measures within 2 weeks before signing the informed consent form, and are willing to abstain from sex or agree to contraception from the signing of the informed consent form until the end of the follow-up period (non-drug contraception is required during the trial, see Section 13.1.2 for details), and have no plans to have children or donate sperm/eggs.

Exclusion criteria

Exclusion Criteria:

-

The following diseases or treatment history:

  1. Any serious clinical diseases such as urinary system, circulatory system, endocrine system, nervous system, digestive system, respiratory system, blood system, immune system, mental and metabolic disorders in the past or currently, or any other diseases that the investigators judge may interfere with the results of the trial, such as intestinal diseases (including irritable bowel syndrome) and urinary tract infection/stones, etc.;
  2. History of malignant tumors (cancers that have been confirmed to have been cured or relieved for ≥5 years, except for radically resected basal cell or squamous cell skin cancer, cervical cancer in situ and resected colon polyps);
  3. Any conditions or diseases that affect the absorption, metabolism and/or excretion of the study drug;
  4. Severe infection, severe trauma or major surgery within 3 months before the screening period or baseline period; or plan to undergo surgery during the trial;
  5. Have used any drug in the 2 weeks before the screening or baseline period (including prescription drugs, over-the-counter drugs, Chinese herbal medicines, dietary supplements, vitamin A and its derivatives, etc., excluding other conventional vitamins and occasional use of acetaminophen), or still within 5 half-lives of the drug during the screening or baseline period (whichever is longer); plan to use non-test drugs during the trial;
  6. Participated in clinical trials of any other drugs or medical devices within 3 months before the screening or baseline period or planned to participate in the study period, or still within 5 half-lives of the drug during the screening or baseline period (whichever is longer);

    Any of the following examinations during screening meet the following criteria:

  7. During the screening or baseline period, sitting systolic blood pressure \<90 mmHg or sitting diastolic blood pressure \<60 mmHg;
  8. During the screening or baseline period, orthostatic hypotension occurs (retest within 15 minutes to confirm);
  9. During the screening or baseline period, abnormal and 12-lead results, male >450ms, female QTcB>460ms;
  10. During the screening or baseline period, serum creatinine exceeding the (ULN);
  11. During the screening or baseline period, \< 70 mL/min/1.73m2 (calculated using the MDRD formula, eGFR (mL/min/1.73m2) = 175×(serum creatinine/88.4)-1.234×age-0.179×(0.79 female), where serum creatinine units are μmol/L);
  12. During the screening or baseline period, (ALT) or aspartate aminotransferase (AST) exceeding 1.2 times ULN, or total exceeding 1.5 times ULN;
  13. During the screening period, any one of the following items is positive: virus surface antigen (HBsAg), antibody, syphilis spirochete antibody or virus antibody;

    General situation:

  14. Pregnant or lactating women, or positive pregnancy test results during the screening period/baseline period;
  15. History of blood donation or severe blood loss (blood loss ≥400 mL) within 8 weeks before the screening period or baseline period, or have received blood transfusion within 4 weeks before the screening period or baseline period; or intend to donate blood during the trial;
  16. Have been vaccinated within 2 weeks before the screening period or baseline period or plan to be vaccinated during the trial;
  17. History of smoking (average daily smoking >5 cigarettes) within 4 weeks before the screening period or baseline period, or cannot stop using any tobacco products during the trial;
  18. Average daily alcohol intake exceeds 15 g (15 g alcohol is equivalent to 450 mL beer, 150 mL of wine or about 50mL of low-alcohol liquor), or cannot abstain from alcohol during the trial; or positive alcohol breath test at baseline;
  19. History of drug abuse or drug dependence before the screening period or baseline period; or positive urine drug test at baseline;
  20. Drink excessive amounts of tea, coffee or caffeinated beverages (more than 8 cups per day, 250 mL per cup) within 6 months before the screening period or baseline period;
  21. Have consumed special foods (such as grapefruit, grapefruit juice or foods/beverages containing grapefruit juice, chocolate, tobacco, alcohol, caffeinated foods or beverages) within 48 hours before the baseline period;
  22. Have special dietary requirements and cannot follow a unified diet;
  23. Have difficulty swallowing, difficulty in venous blood collection, or physical conditions that cannot withstand intensive blood collection;
  24. Other situations in which the researcher determines that the subject is not suitable for participating in this trial, including but not limited to the following: any physical or psychological disease or condition that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Low dose

    Drug: HRS-9813

  • Experimental
    Treatment group B

    High dose

    Drug: HRS-9813

Interventions

  • Initial dose to planned dose(low dose)

  • Initial dose to planned dose(high dose)

06

What researchers measure

Primary outcomes

  1. Safety outcomes: Incidence and severity of AEs.

    Time frame: Day -14 to Day 22

Secondary outcomes

  1. Area under the drug-time curve

    Time frame: Day 1 to Day 22

  2. Area under the steady-state drug-time curve within the dosing interval

    Time frame: Day 1 to Day 22

  3. Peak concentration

    Time frame: Day 1 to Day 22

  4. Time to peak

    Time frame: Day 1 to Day 22

  5. Half-life

    Time frame: Day 1 to Day 22

  6. Apparent clearance

    Time frame: Day 1 to Day 22

  7. Apparent volume of distribution

    Time frame: Day 1 to Day 22

  8. Steady-state trough concentration

    Time frame: Day 1 to Day 22

  9. Steady-state peak concentration[

    Time frame: Day 1 to Day 22

  10. Accumulation ratio (Racc)

    Time frame: Day 1 to Day 22

  11. Proportion of subjects experiencing hypotension during the study

    Time frame: Day 1 to Day 22

07

Study locations

1 site
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality 200080, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jul 2025, 5 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 12, 2025
StartActual
Feb 17, 2025
Primary completionActual
Jul 27, 2025
CompletionActual
Jul 27, 2025
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06821464
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Feb 17, 2025
Primary completion
Jul 27, 2025
Completion
Jul 27, 2025
Last update
Jul 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9813

Start the discussion